AI-designed universal coronavirus vaccine passes first human trial

Researchers at the University of Cambridge and spinout DIOSynVax used machine learning to design a single super-antigen carrying features shared across the whole Sarbeco coronavirus family. In a first-in-human Phase 1 trial of 39 healthy volunteers aged 18 to 50, the needle-free DNA vaccine was safe and triggered immune responses to SARS-CoV-2, SARS and related bat viruses not yet seen in humans. It is the first vaccine whose active ingredient was designed entirely by computer simulations to be tested in people. Published in the Journal of Infection. A larger Phase 2 trial is planned. Sources: University of Cambridge / ScienceDaily, News-Medical, Journal of Infection.

#Shorts

Follow SHORT INFO:
X: @shortinfonews
Bluesky: @shortinfo.bsky.social
TikTok: @shortinfonews
Threads: @shortinfonews
Instagram: @shortinfonews

Видео AI-designed universal coronavirus vaccine passes first human trial канала SHORT INFO